[1] |
YANG Xin, YANG Baochun, YANG Yang, SHAO Huan.
One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
|
[2] |
GAO Caiyun, WANG Boyuan, GAO Xiaojie.
Research Progress in Correlations between SGLT2 Inhibitors and Malignant Tumors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 836-840.
|
[3] |
ZHU Lei, ZHANG Xian, WANG Ruiyan, LI Ying.
Adverse Reactions Reports about Tislelizumab Injection in 447 Cases
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 649-653.
|
[4] |
JI Qiuxia, JIN Jian, ZHANG Bin.
Pharmaceutical care for immune-related adverse events induced by toripalimab
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
|
[5] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[6] |
DING Qian, LI Boyu, ZHANG Qingxia.
Analysis of one case of hemorrhagic goiter caused by aspirin tablets in one patient with coronary heart disease
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 209-212.
|
[7] |
WANG Jiaqing, WANG Qi, SHI Weizhong, ZHANG Dongjie, NING Xiao.
Uncertainty evaluation for the determination of 6-MP in Beagle dog plasma by UPLC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1321-1325.
|
[8] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
[9] |
CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su.
Adverse reactions induced by teriparatide
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
|
[10] |
LI Youjia, XIE Jiao, YAO Hongyi, JI Cheng.
Pharmaceutical care of one case of hypoparathyroid cardiomyopathy
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1254-1257.
|
[11] |
ZHAO Shuang, MIAO Qiuli, SONG Yanqing, LI Yue.
Hypothyroidism Caused by Terepril and Literature Analysis
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 697-699.
|
[12] |
MA Yini, ZHANG Lixiang, ZHANG Zhetao, WANG Xiaoyu, SHI Tianlu.
Adverse Drug Reactions of Anti-thyroid Drugs and Effects of 131I Replacement Therapy in Patients with Hyperthyroidism
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 469-472.
|
[13] |
WANG Shuting, LI Hui, WANG Jiangxue, ZHANG Zixuan, MU Wenbo, GUO Xinmiao, YE Xiangfeng, JIN Hongtao.
Acute and Subchronic Toxicity of Erdosten Ambroxol Hydrochloride Mixture by Gavage in Beagle Dogs
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 24-29.
|
[14] |
FAN Xiaoyu, WANG Yinuo, HUA Manman, LU Xiaochen, WANG Jiangxue, SHAN Yongchao, WEI Jinfeng, JIN Hongtao.
Single and Repeated Dose Toxicity Study of Recombinant Human Factor VIII for Injection in Macaca Fascicularis
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 6-12.
|
[15] |
DU Xiao, WANG Jiannong, HAN Lin, SUN Caixia, CAO Xiaoqiang, SUN Jian.
Repeated Dose Toxicity Study of Antexiao Capsules in Beagle Dogs for 39 Weeks
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 1-5.
|